Department of Cardiology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.
Eur J Heart Fail. 2024 Jun;26(6):1313-1323. doi: 10.1002/ejhf.3268. Epub 2024 May 13.
The emergence of personalized medicine, facilitated by the progress in -omics technologies, has initiated a new era in medical diagnostics and treatment. This review examines the potential of -omics approaches in heart failure, a condition that has not yet fully capitalized on personalized strategies compared to other medical fields like cancer therapy. Here, we argue that integrating multi-omics technology with systems medicine approaches could fundamentally transform heart failure management, moving away from the traditional paradigm of 'one size fits all'. Our review examines how omics can enhance understanding of heart failure's molecular foundations and contribute to a more comprehensive disease classification. We draw attention to the current state of medical practice that only relies on clinical evidence and a number of standard laboratory tests. At the same time, we propose a shift towards a universal approach that uses quantitative data from multi-omics to unravel complex molecular interactions. The discussion centres around the potential of the transition as a means to enhance individual risk assessment and emphasizes management within clinical settings. While the use of omics in cardiovascular research is not recent, many past studies have focused only on a single omics approach. In order to achieve a better understanding of disease mechanisms, we explore more holistic approaches using genomics, transcriptomics, epigenomics, and proteomics. This review concludes with a call to action to adopt multi-omics in clinical trials and practice to pave the way for more personalized disease management and more effective heart failure interventions.
个体化医学的出现得益于组学技术的进步,开创了医学诊断和治疗的新时代。本篇综述考察了组学方法在心力衰竭中的应用潜力,与癌症治疗等其他医学领域相比,心力衰竭在个体化策略方面尚未充分利用。我们认为,将多组学技术与系统医学方法相结合,可以从根本上改变心力衰竭的管理方式,摆脱传统的“一刀切”模式。我们的综述考察了组学如何增强对心力衰竭分子基础的理解,并有助于更全面的疾病分类。我们提请注意当前仅依赖临床证据和少数标准实验室检测的医疗实践现状。同时,我们提出向使用多组学的定量数据来揭示复杂分子相互作用的通用方法转变。讨论围绕着这种转变作为增强个体风险评估的一种手段的潜力,并强调了在临床环境中的管理。尽管组学在心血管研究中的应用并非新鲜事,但过去的许多研究仅关注单一的组学方法。为了更好地理解疾病机制,我们探索了使用基因组学、转录组学、表观基因组学和蛋白质组学的更全面的方法。这篇综述最后呼吁在临床试验和实践中采用多组学,为更个体化的疾病管理和更有效的心力衰竭干预铺平道路。